期刊文献+

体脂分布与代谢综合征、颈动脉内膜中层厚度及尿白蛋白排泄率 被引量:5

Body Fat Distribution and Metabolic Syndrome,Carotid Arterial Intima-media Thickness,Urinary Albumin Excretion Rate
原文传递
导出
摘要 目的探讨体脂分布特点与代谢综合征(MS)、颈动脉内膜中层厚度(IMT)及尿白蛋白排泄率(UAER)的关系。方法2006-2008年于我院行健康体检者182例为研究对象,未经降血糖、降血脂、利尿、降压、抗尿酸药物治疗。在脐水平测定腰围和CT测定内脏脂肪面积及体脂分布,多普勒超声心动仪测量颈动脉IMT,散射比浊法测定UAER。将研究对象分组为内脏型肥胖组[腰围≥90(男)或≥85cm(女),内脏脂肪面积≥100cm2,n=71)、皮下型肥胖组[腰围≥90(男)或≥85cm(女),内脏脂肪面积<100cm2,n=80]及正常对照组[腰围<90(男)或<85cm(女),n=31]。结果内脏型肥胖组MS发生率高于皮下型肥胖组(63.7%比31.9%,P<0.01)。内脏型肥胖组IMT高于皮下型肥胖组[(0.95±0.14)比(0.77±0.12)mm,P<0.05]与正常对照组[(0.71±0.13)mm,P<0.05]。内脏型肥胖组UAER高于皮下型肥胖组[(31.05±19.87)比(22.75±9.32)mg/24h,P<0.01]与正常对照组[(9.95±6.23)mg/24h,P<0.01]。皮下型肥胖组UAER高于正常对照组(P<0.05)。Spearman秩相关分析显示内脏脂肪蓄积随代谢综合征组分增加而增加(r=0.65,P<0.01)。Pearson直线相关分析显示内脏脂肪蓄积与IMT、UAER呈正相关(r=0.59,P<0.01;r=0.61,P<0.01);皮下脂肪蓄积与UAER呈正相关(r=0.53,P<0.05)。多元逐步线性回归分析显示内脏脂肪面积、高密度脂蛋白胆固醇(HDL-C)、收缩压及低密度脂蛋白胆固醇可用作IMT的解释变量;内脏脂肪面积、空腹血糖及HDL-C可作为UAER的解释变量。结论内脏型肥胖MS发生率高于皮下型肥胖,颈动脉IMT主要受内脏脂肪蓄积影响,UAER既受内脏脂肪影响也受皮下脂肪影响。 Objective To study the relationship between body fat distribution and metabolic syndrome (MS), carotid arterial intima-media thickness (IMT), urinary albumin excretion rate (UAER). Methods A cohort of one hundred eighty-two subjects underwent annual health check-up and without any medication were enroIled. Waist circumference (WC) were measured and body fat distribution was measured by computed tomography (CT) scanning at umbilical level. Carotid artery IMT was measured by eehocardiography, and UAER was measured using nephe- [ometry. The suhiects were classified as visceral obesity (mate WC ≥90 cm and that of females ≥85 cm, and visceral fat area ≥100 cm2 , n=71), subcutaneous obesity (male WC ≥90cm and that of females ≥85 cm, and visceral fat area 〈100 cm2 , n=80) and normal (male WC〈90 cm and that of females〈85 cm, n=31). Results The incidence of MS in visceral obesity was significantly higher than that in subcutaneous obesity (63.7% vs 31.9%, P〈0.01). Carotid artery IMT was higher in visceral obesity, compared with that in subcutaneous obesity [ (0.95±0.14) vs (0. 77±0.12) mm, P〈0.05] vs normal [(0.71±0.13) mm, P〈0.05]. UAER was higher in visceral obesity, compared with that in subcutaneous obesity [(31.05±19.87) vs (22.75± 9.32) mg/24 h, P〈0.0.1-1 vs normal I-(9.95±6.23) rag/24 h,. P%0.01]. UAER was higher in subcutaneous obesity, compared with that in normal (P^0.05). Spearman's rank correlation analysis showed, the accumulatiom of visceral fat was elevated with increasing metabolic syndrome components (r= 0.65, P〈0.01). Pearson linear correlation analysis showed that the accumulatiom of visceral fat was positively correlated with IMT and UAER (r= 0.59, P〈0.01; r=0.61, P〈0.01 ; respectively), and subcutaneous fat also positively correlated with UAER (r=0.53, P〈0.05). Stepwise multiple regression analysis showed that visceral fat area, HDL-C, SBP, LDL-C were predisposing risk factors fdr IMT, and visceral fat area, FBG, HDL-C for UAER. Conclusion Visceral obesity was associated with higher incidence rate of MS than that of subcutaneous obesity. Carotid artery IMT are more likely related to viscer- al obesity than that subcutaneous obesity. UAER were influenced concomitantly both by visceral and subcutaneous obesity.
出处 《中华高血压杂志》 CAS CSCD 北大核心 2009年第11期975-979,共5页 Chinese Journal of Hypertension
关键词 内脏脂肪 代谢综合征 颈动脉内膜中层厚度 尿白蛋白排泄率 Visceral fat Metabolic syndrome Carotid arterial intima-media thickness Urinary albumin excretion rate
  • 相关文献

参考文献2

二级参考文献13

  • 1World health organization. Definition, diagnosis and classification of diabetes mellitus and its complications-part1: diagnosis and classification of diabetes mellitus[J].Geneva:WHO,1999.
  • 2Rantala AO, Kauma H, Lilja M,et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects[J].J Inter Med,1999,245:163-74.
  • 3Greenlund KJ,Valdez R,Casper ML,et al.Prevalence and correlates of the insulin resistance syndrome among native Americans[J].Diabetes Care,1999,22:441-447.
  • 4Laaksonen DE,Lakka HM,Salonen JT,et al.Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome[J].Diabetes Care,2002,25:1612-8.
  • 5Liu S,Manson JE. Dietary carbohydrates, physical inactivity, obesity, and the "metabolic syndrome" as predictors of coronary heart disease[J].Curr Opin Lipid,2001,12:395-404.
  • 6Vitaliano PP,Scanlan JM,Zhang J,et al. A path model of chronic stress, the metabolic syndrome, and coronary heart disease[J].Psycho Med,2002,64:418-35.
  • 7Everson SA,Lynch JW,Kaplan GA,et al.Stress-induced blood pressure reactivity and incident stroke in middle-aged men[J].Stroke,2001,157:1006-1008.
  • 8Markovitz JH,Shuster JL,Chitwood ws,et al.Platelet activation in depression and effects of sertraline treatment:an open-label study[J].Am J Psych,2000,157:1006-1008.
  • 9Mittendorfer B, Sidossis LS. Mechanism for the increase in plasma triacylglycerol concentrations after consumption of short term, high-carbohydrate diets[J].Am J Clin Nutr,2001,73:892-899.
  • 10Angela A,Rivellese,Claudia De Natale,et al.Type of dietary fat and insulin resistance[J].Ann N.Y.Acad.Sci,2002,967:329-335.

共引文献70

同被引文献28

  • 1贾伟平.肠促胰素类药物治疗2型糖尿病的评价及展望[J].中华糖尿病杂志,2010,2(6). 被引量:3
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5215
  • 3Gokulakrishnan K,Deepa M,Monickaraj F,et al .Relationship of body fat with insulin resistance and cardiometabolic risk factors among normal glucose-tolerant subjects [J].J Postgrad Med,2011,57 (3): 184-188.
  • 4Bergenstal R,Lewin A,Bailey T,et al.Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemie control with metformin and a sulfonylurea[J].Curr Med Res Opin,2009,25(1):65-75.
  • 5Horton ES,Silberman C,Davis KL, et al.Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database[J].Diabetes Care,2010,33(8): 1 759-1 765.
  • 6Glass LC,Qu Y,Lenox S,et al.Effects of exenatide versus insulinanalogues on welBht change in subjects with type 2 diabetes: a pooled post-hoc analysis[J].Curr Med Res Opin,2008,24(3):639-644.
  • 7K/m MH,Lee MK.The incretins and pancreatic beta-ceils: use of glucagon-like peptide.l and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes mellitus [J].Korean Diabetes J, 2010,34(1):2-9.
  • 8Anagnostis P,Athyros VO,Adarnidou F,et al.Olucagon-like peptide-l.based therapies and cardiovascular disease: looking beyond glycaemic control [J].Diabetes Obes Metab,2011,13 (4): 302-312.
  • 9Horton ES,Silberman C,Davis KL,et al.Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients withm~ ~ype 2 diab~es receivins incrctin ~erapies or insulin in a large cohort databue[JI.Diabetes Care,2010,33(8):l 759-I ?65.
  • 10蒋建家,牟伦盼,苏劲波,等.艾塞那肽对口服降糖药治疗欠佳的肥胖2型糖尿瘸患者的疗效及安全性[J].中华糖尿瘸杂志.2011,3(4):305-308.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部